Britain's medicines regulator said on Friday it had approved the COVID-19 vaccine developed by Pfizer and BioNTech for use on 12- to 15-year-olds.
The regulator said it would now be up to the country's Joint Committee on Vaccination and Immunisation (JCVI) to decide whether to go ahead and inoculate this age group.
Children aged 12-15 are already receiving the Pfizer shot in several countries, including the United States and the UAE, while France and Germany are planning to start offering it to that age group this month.
Britain's Health and Social Care department said it would provide an update once the JCVI had made its decision.
The chief executive of the UK Medicines and Healthcare products Regulatory Agency June Raine said in a statement that her agency had carefully reviewed the clinical trial data in children aged 12 to 15 years old.
"(We) have concluded that the Pfizer/BioNTech COVID-19 vaccine is safe and effective in this age group and that the benefits of this vaccine outweigh any risk," she said.
However, giving vaccines to younger people in affluent countries while many parts of the world await doses for older and more vulnerable people has raised concerns.
The World Health Organisation has urged rich countries to give shots to the COVAX scheme instead.
Ukraine issued air raid alerts for Kyiv and the country's eastern half as blasts shook the city of Mykolaiv early on Monday, authorities said, hours after the one-day Easter ceasefire declared by Russian President Vladimir Putin came to an end.
US Vice President JD Vance began a four-day visit to India on Monday and will hold talks with Prime Minister Narendra Modi, as New Delhi rushes to avoid steep US tariffs with an early trade deal and boost ties with the Trump administration.
The Israeli military on Sunday said a review into last month's killing of emergency responders in Gaza found there had been "several professional failures" and that a commander would be dismissed over the incident.
US President Donald Trump is threatening to cut another $1 billion in funding for Harvard University, this time targeting health research, the Wall Street Journal reported on Sunday, as the administration's row with elite schools escalated.